IP Library Granted Patent US 11,338,008
Granted Patent B2
US 11,338,008 · App. 17/031,368 · Granted May 24, 2022

Pharmaceutical composition comprising thrombolytic peptide-tetrahydroisoquinoline conjugate

Inventor: David Chih-Kuang Chou (Taipei, TW)
Assignee: LUMOSA THERAPEUTICS CO., LTD
A61K38/06A61K47/26A61K47/545A61K47/62
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,338,008
App. No.
17/031,368
Granted
May 24, 2022
Kind
B2
Abstract

The present invention provides a pharmaceutical composition comprising a binary conjugate, DC009, which is a conjugate of a thrombolytic peptide (Pro-Ala-Lys) and a tetrahydroisoquinoline compound having two C1-4 alkyl groups via a lysine linking arm, and a pharmaceutical acceptable carrier. The composition has a pH less than 6.5, preferably has a pH about pH 2-5.5 The composition may comprise a pharmaceutical acceptable excipient such as mannitol, sorbitol, sucrose, lactose, or trehalose.

Claims (7)

1. A pharmaceutical composition comprising (a) a compound with the following formula or a pharmaceutically acceptable salt thereof at a concentration of 10 mg/mL:

and (b) a pharmaceutically acceptable excipient at a concentration of about 3.8% w/w or about 5% w/w, wherein the composition has a pH of about 4.5, wherein the pharmaceutically acceptable excipient is mannitol, sorbitol, sucrose, lactose, or trehalose, where the composition is clear and colorless.

2. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable excipient is mannitol at a concentration of about 3.8% w/w.

3. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable salt is hydrochloride salt.

4. The pharmaceutical composition according to claim 2 , wherein the pharmaceutically acceptable salt is hydrochloride salt.

5. The pharmaceutical composition according to claim 1 , wherein the pharmaceutically acceptable excipient is mannitol at a concentration of about 5% w/w.

6. The pharmaceutical composition according to claim 5 , wherein the pharmaceutically acceptable salt is hydrochloride salt.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 24, 2020
From: CHOU, DAVID CHIH-KUANG
To: LUMOSA THERAPEUTICS CO., LTD
Reel/Frame 053876/0437 →
Continuity (2)
Provisional Application 62905679 · Sep 25, 2019
Related Publication 20210085747A1 · Mar 25, 2021